| Trial Identifier: | 208887 Sub Study 6 |
| Sponsor: | GlaxoSmithKline |
| Start Date: | July 2022 |
| Primary Completion Date: | April 2025 |
| Study Completion Date: | March 2027 |
| Condition: | Myeloma |
For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.
| Language | Description |
| Country | Location |
|---|---|
| Brazil, Bahia | Salvador, Bahia, Brazil, 41253-190 |
| Brazil, São Paulo | São Paulo, Brazil, 04537-080 |
| Canada, NS | Halifax, NS, Canada, B3H 1V7 |
| France | VILLEJUIF CEDEX, France, 94805 |
| Germany, Hamburg | Hamburg, Germany, 22083 |
| Greece | Athens, Greece, 11528 |
| Korea, Republic of | Seoul, Korea, Republic of, 06591 |
| Korea, Republic of | Seoul, Korea, Republic of, 03080 |
| Korea, Republic of | Seoul, Korea, Republic of, 06351 |
| Korea, Republic of | Ulsan, Korea, Republic of, 44033 |
| Mexico, Mexico City | Mexico City, Mexico, 01330 |
| United States, MA | Boston, MA, United States, 02215 |
Powered by
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.
Copyright © 2026 Pharma Intelligence UK Limited (Citeline), a Norstella company